The FDA has approved the sNDA for Mycamine for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients aged <4 months.
Adult heart transplants from hepatitis C virus-positive donors appear safe, with no increased risk for adverse effects on one-year survival.
Researchers evaluated the frequency of polyautoimmunity and its associated factors in a large retrospective cohort of patients with systemic lupus erythematosus.
The FDA has approved Ervebo (Ebola Zaire vaccine, live) for the prevention of disease caused by Zaire ebolavirus in individuals ≥18 years of age.
Leishmaniasis is a neglected tropical disease that is transmitted by phlebotomine sand flies infected with Leishmania parasites.
Patients with recurrent Clostridioides difficile infection (CDI) were less likely to develop bloodstream infections (BSI) if treated with fecal microbiota transplantation (FMT) compared with antibiotics.
Arakoda (tafenoquine; 60 Degrees Pharmaceuticals) has been made available in the US for the prevention of malaria in patients aged ≥18 years.
A review finds that fluconazole is the only commercially available evidence-based option for systemic treatment of cutaneous candidiasis.
The FDA has approved Fetroja for the treatment of complicated urinary tract infections.
The FDA has granted QIDP designation and Fast Track designation to ATM-AVI for treatment of complicated intra-abdominal infections and more.
